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Abstract
Background: There is growing recognition for the consequences of rectal cancer treatment to maintain an
adequate functional sphincter in the long-term rather than preserving the anal sphincter itself. This study aims to
evaluate long-term effects of neoadjuvant chemoradiotherapy (nCRT) followed by sphincter-preserving resection on
anal sphincter function in relation to quality of life (QoL) among locally advanced rectal cancer patients.
Methods: Twenty-nine patients treated with nCRT followed by low anterior resection surgery were included in this
study. Data on patient demographics, tumor location and symptoms of urgency and fecal soiling were recorded
and evaluated with respect to Wexner Fecal Incontinence Scoring Scale, European Organization for Research and
Cancer (EORTC) cancer-specific (EORTC QLQ-C30) and colorectal cancer-specific (EORTC QLQ-CR38) questionnaires
and anorectal manometrical findings. Correlation of manometrical findings with Wexner Scale, EORTC QLQ-CR38
scores and EORTC QLQ-C30 scores was also evaluated.
Results: Median follow-up was 45.6 months (ranged 7.5–98 months. Higher scores for incontinence for gas (p = 0.001),
liquid (p = 0.048) and solid (p = 0.019) stool, need to wear pad (p = 0.001) and alteration in life style (p = 0.004) in
Wexner scale, while lower scores for future perspective (p = 0.010) and higher scores for defecation problems
(p = 0.001) in EORTC QLQ-CR38 were noted in patients with than without urgency. Manometrical findings of
resting pressure (mmHg) was positively correlated with body image (r = 0.435, p = 0.030) and sexual functioning
(r = 0.479, p = 0.011) items of functional scale, while rectal sensory threshold (RST) volume (mL) was positively
correlated with defecation problems (r = 0.424, p = 0.031) items of symptom scale in EORTC QLQ-CR38 and
negatively correlated with social function domain (r = −0.479, p = 0.024) in EORTC QLQ-C30. RST volume was
also positively correlated with Wexner scores including incontinence for liquid stool (r = 0.459, p = 0.024), need
to wear pad (r = 0.466, p = 0.022) and alteration in lifestyle (r = 0.425, p = 0.038).
Conclusion: The high risk of developing functional anal impairment as well as the systematic registration of
not only oncological but also functional and QoL related outcomes seem important in rectal cancer patients
in the long-term disease follow-up.
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Background
Improved neoadjuvant chemoradiotherapy (nCRT) sched-
uling and planning have been associated with well-
documented oncological benefits including down-staging
and downsizing of the tumor leading increased tumor
resectability and thus the higher likelihood of sphincter-
preserving surgery [1–4]. Combined with advancement of
surgical techniques, substantial improvement occurred in
survival from rectal cancer over the past two decades
[5–8]. This translated not only to a larger population
of rectal cancer ‘survivors’ but also increased propor-
tion of number of rectal cancer patients who can
maintain the continuity of the intestine due to more
frequent use of sphincter-preserving surgery by means
of increased usage of nCRT, improved surgical tech-
nique and stapling devices [3, 5, 6].
However, while the greater use of neoadjuvant treat-
ment and surgical techniques and thus survival from
rectal cancer continues to improve, long-term conse-
quences of treatment become unfolding. Consequently a
growing body of evidence indicate that both preoperative
radiotherapy and sphincter-preserving resection are
likely to impair anorectal and sexual functions leading
persistent dysfunctional symptoms which may have the
potential to significantly impact on quality of life (QoL)
[9–12], even more than a permanent stoma after abdo-
minoperineal excision (APE) [13, 14].
As length of survival increases after diagnosis there is
growing recognition for the consequences of cancer
treatment to support patient recovery and optimize
health-related QoL and thus for the importance of main-
taining an adequate functional sphincter in the long-term
rather than preserving the anal sphincter itself [3, 15].
Therefore, the present study was designed to evaluate
long-term effects of nCRT followed by sphincter-
preserving resection on anal sphincter function in relation




Of 74 patients with locally advanced (T3/T4 or N+)
rectal adenocarcinoma who received nCRT prior to low
anterior resection surgery between 2006 and 2013 and
followed without any clinical or radiological disease pro-
gression, metastasis or recurrence thereafter, 29 patients
(mean ± SD age: 54.7 ± 12.6 years, 51.7 % were males)
were included in the study. None of patients had fecal
soiling and thus complaints indicating presence of anal
sphincter dysfunction at the time of diagnosis.
Written informed consent was obtained from each
subject following a detailed explanation of the objectives
and protocol of the study which was conducted in
accordance with the ethical principles stated in the
“Declaration of Helsinki” and approved by Marmara
University School of Medicine Ethical Committee (refer-
ence no: 09.2011.0162, date: 24/11/2011).
Study parameters
Data on patient demographics, tumor characteristics
(preoperative stage, location, histological type, histo-
logical grade, postoperative stage, vascular invasion, and
perineural invasion), treatment (nCRT, adjuvant chemo-
therapy) and treatment response (pathological) and
symptoms of urgency and fecal soiling were recorded.
Fecal incontinence was evaluated based on Wexner
Fecal Incontinence Scoring Scale. Manometrical assess-
ment of anal sphincter function was performed using
anorectal manometry. Health-related quality of life
(HRQoL) was evaluated with European Organization for
Research and Cancer (EORTC) cancer-specific (EORTC
QLQ-C30) and colorectal cancer-specific (EORTC QLQ-
CR38) QoL questionnaires (QLQ). Manometrical findings
of anal sphincter function, Wexner Fecal Incontinence
Scoring Scale findings, EORTC QLQ-CR38 scores and
EORTC QLQ-C30 scores were evaluated with respect to
tumor location, gender and symptoms of urgency and
fecal soiling. Correlation of manometrical findings with
Wexner anal incontinence scores, EORTC QLQ-CR38
scores and EORTC QLQ-C30 scores was also evaluated.
Chemoradiotherapy and surgery
Computed tomography (CT) simulation and 3D conformal
treatment planning were performed in all patients. Radio-
therapy was given with high-energy (15 or 18 MV photon)
linear accelerator with 1.8 Gy per fraction to a total dose of
45–50.4 Gy in 25–28 fractions. During the whole CRT
period all patients received 5-fluorouracil-based chemother-
apy (400 mg/m2, i.v. bolus, at 1st and 5th week of radiother-
apy or fluoropyrimidine 300 mg/m2/day, oral). Patients
entered the study following the sphincter preserving
surgery (low anterior resection) which was performed 6–8
weeks after nCRT and all had transient loop ileostomy and
stoma reversal.
Wexner fecal incontinence scoring scale
The Wexner Fecal Incontinence Scoring Scale [16] has
become a widely used for the assessment of severity of
fecal incontinence and has been validated to Turkish
population, previously [17]. This scale included five
questions that were three about anal incontinence (gas,
liquid, and solid), a coping mechanism (pad wear), and a
lifestyle question (alteration). Volunteers were instructed
to rate the frequency of stool loss, frequency of use of
coping behavior, and frequency of lifestyle alteration
through the use of quantifiers (0 = never, 1 = rarely,
2 = sometimes, 3 = usually, 4 = always). The score was
calculated by totaling the numerical values associated
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with the quantifiers. It provides a single anal incontinence
severity score and higher scores indicate the severity of
symptoms. The total score of the instrument ranged from
0 (no incontinence) to 20 (complete incontinence).
Anorectal manometry
Anal sphincter manometry was performed median
17.3 months (mean 30 months, ranged 3–86 months)
after the restorative surgery. Manometry was carried out
by a pre-calibrated, water perfusion system (Mui Scientific
Ontorio Canada model PIP-4-8SS), using a single use
catheter with 8 holes 0.5 cm apart (Sandhill Scientific,
CO, USA, SUAMC-M83A-10). Manometrical data was
stored and analyzed with computer software (Sandhill
Scientific Insight g3 Highlands Ranch, Colorado,
USA). Bowel was prepared by enema (Fleet Enema,
C.B. Fleet Co. Inc. USA). Patients were placed com-
fortably in the left lateral position. After the insertion
of the catheter into the rectum, maximal resting pres-
sure (MRP) and maximal squeeze pressure (MSP)
measurements were done. MRP was defined as the
average of maximal pressures obtained from all holes
by stationary pull-through technique. MSP was de-
fined as the mean of differences between the mean
pressures obtained by voluntary squeezing for 5 s and
resting pressures when all of the holes were within the
anal canal. Patients were instructed to squeeze their
anus as much as they could without squeezing their
abdominal and buttock muscles throughout the entire
period of MSP measurement in order to record actual
sphincter pressures and to prevent pressure interac-
tions. Minimum balloon volume that can be sensed
was defined as rectal sensory threshold (RST) and
minimal balloon distention volume that causes anal
sphincter relaxation was defined as minimal balloon
distention volume causing rectoanal inhibitory reflex
(RAIR). We could not measure RAIR volume in 9
patients due to occurrence of anal pain.
EORTC QLQ-C30
The EORTC QLQ-C30 is a 30-item general cancer
instrument that evaluates 5 domains of QoL (physical,
role, cognitive, emotional, and social), 9 symptom scales
(fatigue, nausea/vomiting, pain, dyspnea, sleep disturb-
ance, appetite loss, constipation, diarrhea, and financial
impact), and a global QOL score. Each domain of QoL
is assessed by 2–5 questions, and responses are scored
on a 4-point Likert scale, with higher scores representing
better QoL, whereas higher scores on symptom items
represent worse symptoms. The validity and reliability of
the QLQ-C30 has been well documented [18]. The
reliability and validity of the Turkish version of QLQ-
C30 has been confirmed [19].
EORTC QLQ-CR38
The 38-item QLQ-CR38 is a colorectal cancer specific
instrument that includes 4 functional domains (body
image, sexual functioning, sexual enjoyment, and future
perspective) and 8 symptom scales (micturition problems,
chemotherapy side effects, symptoms associated with the
gastrointestinal tract, male sexual problems, female sexual
problems, defecation problems, stoma-related problems,
and weight loss) [20]. Higher functional domain scores
indicated increased function, and higher symptom scores
signified more severe symptoms.
Statistical analysis
Analyses were done in MedCalc Statistical Software ver-
sion 12.7.7 (MedCalc Software bvba, Ostend, Belgium;
http://www.medcalc.org; 2013). Median follow-up was
calculated from the initiation of CRT. Manometrical
scores of groups were compared using Mann–Whitney
U test. Associations between parameters of Wexner
scores, QoL scales, manometrical scores and complaints
of patients (urgency or soiling) were assessed with
Spearman test. Continuous variables are presented as
mean ± SD or median (range) according to distribution
of data p < 0.05 were considered statistically significant.
Results and discussion
Demographic and clinical characteristics of patients
Demographic and clinical characteristics of patients are
summarized in Table 1. Median follow-up was 45.6 months
(ranged 7.5–98 months). Most of patients had preoperative
T3N1 (62.1 %) stage, distal (48.3 %) or mid-rectal (37.9 %),
high grade (69.0 %) adenocarcinoma.
nCRT was applied using three dimensional linear acceler-
ator radiotherapy in all patients, at 50.4 Gy dose in 62.1 %
of patients and with FUFA Mayo chemotherapy regimen in
86 %. Two cT2N0 patients in our study received nCRT
since they did not want to have APR surgery CRT related
complications were observed in 58.6 % (Grade 1 in 24.1 %
and Grade 2–3 in 34.5 %) of patients. Being assessed in 11
patients based on Ryan tumor regression grade system [21],
pathological response rate was 24.0 %. Symptom of urgency
was determined in 77.0 %, while fecal soiling in 31 % of
patients. Tumor was determined to be located at distal
rectum in 14(48.3 %) patients, mid-rectum in 11(37.9 %)
patients and proximal rectum in 4(13.8 %) patients.
Manometrical findings
Overall, resting pressure was 38.7 ± 21.9 mmHg, MSP was
116.9 ± 59.7 mmHg and RST volume was 28.1 ± 18.8 mL.
Except for significantly higher MSP in males than in females
(138.1 ± 62.7 mmHg vs. 94.1 ± 48.7 mmHg, p = 0.023),
no significant difference was noted in manometrical
findings with respect to tumor location, gender and
symptoms of urgency and fecal soiling (Table 2).
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Wexner fecal incontinence scores
Total Wexner score was median 10.0 with no difference
in component scores with respect to tumor location,
while a significant influence of gender and symptoms on
incontinence scores. Scores of incontinence for solid
stool (p = 0.029) and alteration in life style (p = 0.012)
were significantly higher males than in females. In pa-
tients with than without urgency, significantly higher
total scores (p < 0.001) and component scores of in-
continence for gas (p = 0.001) and liquid (p = 0.048)
and solid (p = 0.019) stool as well as for need to wear
pad (p = 0.001) and alteration in life style (p = 0.004)
were determined. In patients with than without fecal
soiling, scores of incontinence for solid stool (p = 0.039)
and alteration in life style (p = 0.034) were significantly
higher (Table 3).
Correlation of manometrical findings with Wexner Fecal
Incontinence scores
RST volume was positively correlated with incontinence
for liquid stool (r = 0.459, p = 0.024), need to wear pad
(r = 0.466, p = 0.022) and alteration in lifestyle (r = 0.425,
p = 0.038) components of Wexner scale. Minimal bal-
loon distention volume causing RAIR was positively
correlated with incontinence for liquid stool (r = 0.586,
p = 0.008) (Table 4).
No significant difference was noted in Wexner as well
as QoL scores with respect to minimal balloon disten-
tion volume causing or not causing RAIR (Table 5).
EORTC QLQ-CR38 scores
Overall scores for functional and symptoms scales of
EORTC QLQ-CR38 are shown in Table 6. Tumor loca-
tion could not be evaluated. No significant difference
was noted with respect to gender and symptoms of fecal
soiling. Patients with than without urgency symptom
have significantly lower scores for future perspective
(p = 0.010) and sexual functioning (p = 0.016) items of
functional scales, while higher scores for chemother-
apy side effects (p = 0.023) and defecation problems
(p = 0.001) items of symptoms scales (Table 6).
Correlation of manometrical findings with EORTC
QLQ-CR38 scores
Resting pressure (mmHg) was positively correlated with
body image (r = 0.435, p = 0.030) and sexual functioning
Table 1 Demographic and clinical characteristics of patients
(n = 29)











Distal rectum 14 (48.3)
Mid-rectal 11 (37.9)
Proximal rectum 4 (13.8)
RT dose, n (%)
50.4 Gy 18 (62.1)
56 Gy 7 (24.1)
46 Gy 4 (13.8)
Concomitant CT, n (%)
FUFA Mayo 25 (86)
UFT+Antrex 4 (13.8)
CRT related complications, n (%)
None 12 (41.4)
Grade 1 7 (24.1)
Grade 2–3 10 (34.5)








Pathological response, n (%) n = 29
Complete response 7 (24.0)
Stable 10 (35.0)
Partial regression 12 (41.0)
Vascular invasion, n (%) n = 27 8 (29.6)
Perineural invasion, n (%) n = 27 6 (22.2)




Table 1 Demographic and clinical characteristics of patients
(n = 29) (Continued)
FOLFOX 1 (4.8)
Urgency, n (%) 21 (77.0)
Fecal soiling, n (%) 9 (31.0)
XELOX Capacitabine and oxaliplatin, FOLFOX Fluorouracil and oxaliplatin
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Table 2 Manometrical findings with respect to tumor location, gender and symptoms of urgency and fecal soiling
Total Tumor location Gender Urgency Fecal soiling
Distal rectum Mid-rectal Female Male (+) (−) (+) (−)
Resting pressure (mmHg) na 27 13 10 13 14 19 8 9 18
Mean ± SD 38.7 ± 21.9 32.4 ± 14.0 43 ± 24.0 42.5 ± 26.7 35.1 ± 16.4 33.3 ± 15.6 51.5 ± 29.7 30.6 + 14.0 42.7 + 24.2
Median (min-max) 33.0 (12–96) 26 (17–62) 41 (16–88) 33 (12–96) 25.5 (17–62) 26 (12–62) 42.5 (19–96) 24 (17–54) 36 (12–96)
p valueb - 0.456 0.720 0.137 0.226
Maximal squeeze pressure (mmHg) na 29 14 11 14 15 21 8 9 20
Mean ± SD 116.9 ± 59.7 110.3 ± 56.0 125.3 ± 49.8 94.1 ± 48.7 138.1 ± 62.7 109.5 + 56.2 136.4 + 68.2 135.8 + 77.8 108.4 + 50.0
Median (min-max) 103.0 (35–273) 95 (39–240) 117 (35–211) 83.5 (39–211) 131 (35–273) 103 (35–240) 101.5 (73–273) 105 (35–273) 95 (39–211)
p valueb - 0.273 0.023 0.305 0.409
RST volume (mL) na 26 11 11 13 13 18 8 8 18
Mean ± SD 28.1 ± 18.8 27.3 ± 15.6 30.9 ± 24.7 22.3 ± 7.3 33.8 ± 24.7 30.6 + 21.5 22.5 + 8.9 25 + 13.1 29.4 + 21.0
Median (min-max) 20.0 (10–100) 20 (10–60) 20 (10–100) 20 (10–30) 20 (10–100) 20 (10–100) 20 (10–40) 20 (10–50) 20 (10–100)
p valueb - 0.945 0.418 0.387 0.571
MBDV causing RAIR (mL) na 20 8 8 12 8 14 6 6 14
Mean ± SD 27.5 ± 10.2 26.3 ± 7.4 27.5 ± 11.6 25 ± 6.7 31.3 ± 13.6 26.4 ± 9.3 30 ± 12.6 31.7 ± 11.7 25.7 ± 9.4
Median (min-max) 20(20–50) 25(20–40) 25(20–50) 20(20–40) 25(20–50) 20(20–50) 25(20–50) 30(20–50) 20(20–50)
p valueb - 0.959 0.427 0.659 0.274
RST Rectal sensory threshold, MBDV Minimal balloon distension volume, RAIR Rectoanal inhibitory reflex












Table 3 Wexner Fecal Incontinence Scores with respect to tumor location, gender and symptoms of urgency and fecal soiling
Total Tumor location in rectum Gender Urgency Fecal soiling
Prox. Mid. Distal F M (+) (−) (+) (−)
Wexner scale components Median (min-max) Median (min-max) Pa Median (min-max) Pb Median (min-max) Pb Median (min-max) pb
Incontinence for gas 4.0 (0–4) 2 (0–4) 4 (0–4) 4 (0–4) 0.662 3.5 (0–4) 4 (0–4) 0.458 4 (0–4) 0 (0–4) 0.001 4 (0–4) 4 (0–4) 0.658
Incontinence for liquid stool 0 (0–4) 0 (0–4) 0 (0–4) 2.5 (0–4) 0.753 0 (0–4) 3 (0–4) 0.169 3 (0–4) 0 (0–3) 0.048 0 (0–4) 0 (0–4) 0.418
Incontinence for solid stool 0 (0–4) 0 (0–4) 0 (0–4) 0.5 (0–4) 0.779 0 (0–4) 4 (0–4) 0.029 3 (0–4) 0 (0–0) 0.019 0 (0–4) 0 (0–4) 0.039
Need to wear pad 2 (0–4) 0.5 (0–4) 3 (0–4) 2.5 (0–4) 0.649 0.5 (0–4) 4 (0–4) 0.068 3.5 (0–4) 0 (0–1) 0.001 1 (0–4) 1 (0–4) 0.051
Alteration in lifestyle 2 (0–4) 0.5 (0–4) 3 (0–4) 2 (0–4) 0.689 0 (0–4) 4 (0–4) 0.012 3 (0–4) 0 (0–1) 0.004 0 (0–4) 0 (0–4) 0.034
Total score 10 (0–20) 3 (0–20) 11 (0–20) 10.5 (0–20) 0.690 4 (0–20) 16 (0–20) 0.061 14.5 (0–20) 0 (0–4) <0.001 4 (0–20) 4 (0–20) 0.106
aKruskal Wallis test, bMann-Whitney U test. Bold values indicate statistical significance at α=0.05 level












(r = 0.479, p = 0.011) items of functional scale. RST vol-
ume was positively correlated with defecation problems
(r = 0.424, p = 0.031) and weight loss (r = 0.445, p = 0.023)
items of symptom scale in EORTC QLQ-CR38 (Table 7).
EORTC QLQ-C30 scores
Overall scores for functional and symptoms scales of
EORTC QLQ-C30 are shown in Table 8. Tumor location
could not be evaluated. No significant difference was
noted with respect to gender. Global QoL/general health
status (GHS) scores were significantly lower in patients
with than without urgency (p = 0.039) or fecal soiling
(9 = 0.008) symptoms. Role function scores of func-
tional scale were significantly lower in patients with
than without urgency (p = 0.020), while emotional func-
tion scores (p = 0.032) of functional scale and fatigue score
(p = 0.043) of symptom scale were significantly lower in
patients with than without fecal soiling (Table 8).
Correlation of manometrical findings with EORTC
QLQ-C30 scores
Except for significant negative correlation of social func-
tion scores of functional scales to RST volume (r = −0.479,
p = 0.024), no correlation was noted between EORTC
QLQ-C30 scores and manometrical findings (Table 9).
In the present cohort of locally advanced rectal cancer
patients treated with nCRT and sphincter-preserving
resection, after a median follow up of 45.6 months, ano-
rectal manometry performed after median 17.3 months
of restoration revealed an average resting pressure
(38.7 mmHg) and MSP (116.9 mmHg) of below the nor-
mal ranges (60–80 mmHg and >120 mmHg, respect-
ively) [22]. Average Wexner score (10.0) was consistent
with severe fecal incontinence (scores ≥10) [22, 23],
while GHS scores were suggestive of poor HRQoL.
Neither the severity of incontinence nor the manome-
trical findings differed with respect to tumor location,
while the presence of urgency and impaired RST
volume were associated with increased severity of
fecal incontinence and poor QoL scores.
Pelvic dysfunction including bowel, urinary and sex-
ual dysfunctions has been reported in up to 25–50 %
of all patients following a sphincter-preserving resec-
tion of the rectum [24–26] as a result of reduced anal
tone, loss of recto-anal inhibitory reflex, and decreased
neorectal volume [5]. nCRT has also been documented
to lead to adverse effects on bowel function based on
vascular toxicity and direct damage to the anal sphinc-
ter muscle leading decrease in anal resting pressure
and colonic compliance and inhibition of the impulse
conduction [9, 11].
Hence, both pelvic radiotherapy and sphincter-preserving
surgery are considered likely to impair anorectal and
sexual functions and thereby to lead poor QoL in rectal
cancer patients [5, 9, 11, 12]. Accordingly our findings
support the emerging literature on late adverse effects
of pre-operative radiotherapy and sphincter-preserving
surgery on bowel function in rectal cancer patients with
restoration of bowel continuity as associated with in-
creased frequency, urgency, incomplete rectal emptying
and fecal leakage/incontinence problems [9, 27–30]
along with a significant impact on QoL [29, 31, 32].
Bowel dysfunction is considered to be most frequent
and severe within the first year of treatment, and then
to stabilize in general [5], while longer persistence of
Table 4 Correlation of manometrical findings with Wexner Fecal Incontinence scores
Manometrical findings
Resting pressure (mmHg) MSP (mmHg) RST volume (mL) MBDV causing RAIR (mL)
Wexner scores for: r p r p r p r p
Incontinence for gas −0.280 0.165 −0.273 0.168 0.324 0.123 −0.022 0.928
Incontinence for liquid stool 0.095 0.646 −0.167 0.404 0.459 0.024 0.586 0.008
Incontinence for solid stool −0.075 0.717 −0.111 0.582 0.396 0.056 0.373 0.116
Need to wear pad −0.10 0.626 −0.121 0.546 0.466 0.022 0.351 0.141
Alteration in lifestyle −0.033 0.873 0.126 0.531 0.425 0.038 0.291 0.226
MSP Maximal squeeze pressure, RST Rectal sensory threshold, MBDV Minimal balloon distension volume, RAIR Rectoanal inhibitory reflex, r Correlation coefficient.
Bold values indicate statistical significance at α=0.05 level
Spearman correlation analysis
Table 5 Wexner scores with respect to minimal balloon
distention volume (causing vs. not causing RAIR)
Minimal balloon distention volume
Med (min-max) RAIR (−) RAIR (+) p valuea
Wexner scores for:
Incontinence for gas 6(1–6) 5(1–6) 0.238
Incontinence for liquid stool 4.5(1–6) 1(1–6) 0.260
Incontinence for solid stool 5.5(1–6) 1(1–6) 0.147
Need to wear pad 5.5(1–6) 3(1–6) 0.132
Alteration in lifestyle 6(1–6) 2(1–6) 0.084
Qol Score 50(25–83.3) 58.3(16.7–100) 0.982
aMann Whitney U test
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Table 6 EORTC QLQ-CR38 scores with respect to tumor location, gender and symptoms of urgency and fecal soiling
EORTC QLQ-CR38 components Total Tumor location in rectum Gender Urgency Fecal soiling
Prox. Mid. Distal F M (+) (−) (+) (−)
Functional scales Median
(min-max)
Median (min-max) Pa Median (min-max) Pa Median (min-max) Pa Median (min-max) Pa



























































































































































































































































the problem extending to 5 years postoperatively has
also been reported in 5–63 % of rectal cancer patients
[5, 33, 34].
Accordingly, albeit it is not possible to discriminate
the impact of surgery or nCRT per se on the bowel
dysfunction, identification of decreased resting pressure
MSP, severe fecal incontinence and presence of urgency
in most of our patients after a median follow up of
45.6 months supports that a considerable proportion of
patients with rectal cancer suffer from bowel dysfunction
for 3–5 years [29, 35–37].
Data on the prevalence of incontinence and urgency
aspects of bowel dysfunction following low anterior resec-
tion revealed large variations in different studies, ranging
from 0 to 51 % and 4 to 68 % respectively [38]. Fecal in-
continence is considered to be a common problem among
patients with rectal cancer after surgery, recovered over
time [39–41] in some patients, while as in our cohort it
may also remain as a long-term problem in some patients
with rectal cancer [5].
Identification of urgency in 77.0 % of our cohort supports
the consideration of urgency as a common defecation
related problem among patients with rectal cancer in the
first 5 years following surgery, experienced by 40–46 % of
patients at year four [29, 37, 40], and 16–38 % at year five
[29, 42]. The significant association of presence of urgency
with severity of all component scores of Wexner fecal
incontinence scale in our cohort supports the association of
the alteration in sensation of defecation after resection with
development of incontinence in operated rectal cancer
patients [43].
Presence of fecal soiling in 30 % of our patients sup-
port that fecal incontinence and consequent loss of con-
trol over defecation are also associated with other
problems such as fecal leaking/soiling among patients
with fecal incontinence as reported in the past studies
with a prevalence ranging from 10 to 69 % during the
first 3 years after surgery [5, 31, 35, 44–46].
In a past study on prospective evaluation of bowel
function after sphincter-preserving surgery for rectal
cancer, decrease in bowel function scores was reported
in 163/266 patients (61.3 %) within the first postopera-
tive year, while the tumor location was reported to be
independently associated with impaired bowel function
in the multivariable analysis [47].
In another study considering the short-term preopera-
tive change of anorectal function based on manometric
data after nCRT, tumor response of chemoradiation was
shown to be significantly associated with sensory thresh-
old for desire to defecate and thus potential benefit of
nCRT on defecatory function and local disease control
has been suggested, at least in the short-term period
after the radiation [48].
However, no difference was noted in manometrical
findings, Wexner scores and cancer specific and colorec-
tal cancer specific QoL measures in the long-term with
respect to tumor location in our cohort of rectal cancer
patients. But it is quite likely that having relatively small
sample size might preclude achieving statistical signifi-
cance in these parameters.
Bowel dysfunction, leading lifestyle changes in 33–58 %
of patients at year one, has been shown to have a profound
Table 7 Correlation of manometrical findings with EORTC QLQ-CR38 scores
Manometrical findings
Resting pressure (mmHg) MSP (mmHg) RST volume (mL) MBDV causing RAIR (mL)
EORTC QLQ-CR38 components r p r p r p r p
Functional scales
Body image (n = 26) 0.435 0.030 0.160 0.435 −0.173 0.420 0.059 0.810
Future perspective (n = 25) 0.081 0.714 0.189 0.365 −0.276 0.214 −0.024 0.931
Sexual functioning (n = 29) 0.479 0.011 0.268 0.160 −0.143 0.486 0.353 0.127
Sexual enjoyment (n = 24) 0.299 0.176 −0.049 0.821 0.091 0.694 0.005 0.985
Symptom scales
Radiation-induced micturition (n = 29) −0.263 0.186 0.015 0.937 −0.091 0.659 −0.411 0.072
Chemotherapy side effects (n = 29) 0.183 0.361 0.004 0.982 −0.203 0.319 −0.344 0.137
Gastrointestinal symptoms (n = 29) −0.304 0.123 −0.232 0.226 0.025 0.904 0.185 0.435
Sexual dysfunction of men (n = 11) −0.087 0.812 −0.304 0.364 0.464 0.176 0.268 0.254
Sexual dysfunction of women (n = 4) 0.775 0.225 −0.258 0.752 −0.577 0.423 0.232 0.325
Defecation problems (n = 29) −0.159 0.429 −0.163 0.398 0.424 0.031 0.242 0.304
Weight loss (n = 29) −0.146 0.468 −0.021 0.913 0.445 0.023 0.00 1.00
MSP Maximal squeeze pressure, RST Rectal sensory threshold, MBDV Minimal balloon distension volume, RAIR Rectoanal inhibitory reflex, r Correlation coefficient
Spearman correlation analysis. Bold values indicate statistical significance at α=0.05 level
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Table 8 EORTC QLQ-C30 scores with respect to tumor location, gender and symptoms of urgency and fecal soiling
Total Tumor location in rectum Gender Urgency Fecal soiling























































































































































































































































































































































effect on daily life and the QoL of patients with rectal can-
cer [46, 49]. Accordingly, GHS scores were suggestive of
poor QoL in our cohort. Sexual functioning and sexual en-
joyment were the mostly affected functional domains and
sexual dysfunction of men and defecation problems were
the most severe symptoms identified on EORTC QLQ-
CR38 in our patients. Likewise, recent research has shown
high levels of sexual dysfunction in males undergoing rec-
tal cancer treatment [6, 11, 28]. However it should be
noted the EORTC QLQ-CR38 only measures sexual inter-
est and enjoyment and not the impact of psychological fac-
tors on sexual functioning which seems an important
component of female sexual dysfunction [6, 50].
Patients with rectal cancer have to adapt themselves
behaviorally and psychologically to manage bowel dys-
function via lifestyle changes such as taking drugs, using
pads, modifying diet, and reducing social activities to
avoid occurrence of bowel accidents in public places [13,
51]. Accordingly, social function was the mostly affected
functional domain and financial impact was amongst the
most severe symptoms in EORTC QLQ-C30 in our co-
hort which seems consistent with the inverse association
reported between bowel dysfunction and social function-
ing [29, 52] and the higher likelihood of financial diffi-
culties in patients reporting greater defecation problems
[6, 29] reported in the past studies.
Although fecal incontinence after radiotherapy has
been reported to affect QoL of rectal cancer patients in
significant and persistent manner [53], urgency and
clustering were suggested to have a much higher
impact on QoL than fecal incontinence [38]. A statis-
tically significant association between urgency and incom-
plete emptying and QoL, but not between incontinence
and QoL was also reported in rectal cancer patients [54].
Notably, in addition to its significant association with
severity of fecal incontinence, urgency was also associ-
ated with poorer function in future perspective and
sexual functioning domains of EORTC QLQ-CR38 along
with increased severity of chemotherapy related side
effects and defecation problems in our cohort. Presence
of urgency and fecal soiling symptoms were also associ-
ated with poor GHS scores along with poor role func-
tion and emotional function, respectively on EORTC
QLQ-C30.
With no significant difference in terms of manometri-
cal findings, severity of fecal incontinence and poor colo-
rectal cancer-specific QoL were more pronounced in
patients with than without urgency in our cohort. Indeed,
impaired RST volume and presence of urgency were the
two parameters that showed the highest positive associ-
ation with Wexner fecal incontinence scores. Besides,
RST volume was correlated negatively with social function
Table 9 Correlation of manometrical findings with EORTC QLQ-C30 scores
Manometrical findings
Resting pressure (mmHg) MSP (mmHg) RST volume (mL)
EORTC QLQ-C30 components r p r p r p
Global QoL/GHS 0.188 0.347 −0.072 0.711 −0.070 0.734
Functional scales
Physical function 0.090 0.657 −0.046 0.813 −0.0257 0.205
Role function 0.096 0.662 0.194 0.363 −0.092 0.683
Emotional function 0.276 0.163 −0.056 0.778 −0.043 0.839
Cognitive function −0.004 0.986 −0.185 0.337 −0.095 0.646
Social function 0.366 0.086 0.070 0.741 −0.479 0.024
Symptom scales
Fatigue 0.235 0.248 −0.042 0.834 −0.080 0.710
Nausea/vomiting −0.208 0.299 −0.141 0.467 −0.135 0.510
Pain −0.305 0.122 −0.054 0.779 0.181 0.377
Dyspnea −0.250 0.209 0.163 0.400 0.215 0.290
Sleep disturbance −0.265 0.182 0.030 0.876 0.254 0.210
Loss of appetite −0.108 0.592 −0.107 0.581 −0.097 0.638
Constipation −0.034 0.866 0.239 0.211 −0.025 0.902
Diarrhea 0.292 0.139 0.319 0.092 −0.042 0.840
Financial impact −0.066 0.745 0.076 0.696 0.202 0.323
MSP Maximal squeeze pressure, RST Rectal sensory threshold, r correlation coefficient
Spearman correlation analysis. Bold values indicate statistical significance at α=0.05 level
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domain of EORTC QLQ-C30, while the resting pressure
was positively correlated with body image and sexual
functioning domains of EORTC QLQ-CR38. On the basis
of GHS scores suggestive of poor QoL and the correlation
of urgency as well as manometrical findings, RST volume
in particular, with QoL scores and no alteration in mano-
metrical findings with respect to urgency; anorectal
dysfunction seems to translate in an impairment of the
QoL scores in our cohort.
Sphincter-saving surgery is generally preferable to APE
among patients with rectal cancers given that it enables
restored bowel continuity [6]. However, manometrical
findings were suggestive of significant bowel dysfunction,
while Wexner scores indicated severe fecal incontinence
and poor scores were noted on functional and symptom
domains of cancer specific and colorectal cancer specific
QLQ in our cohort. Hence, our findings indicate long-term
adverse effects of nCRT and sphincter-preserving surgery
on bowel function and QoL in rectal cancer patients. Given
the likelihood of overall QoL scores to be similar in patients
with a stoma compared to those with re-continuity [6, 55],
our findings emphasize that maintaining an adequate func-
tional sphincter is more important than preserving the anal
sphincter itself in terms of avoiding the gastrointestinal late
effects including fecal incontinence and improving the pa-
tients’ QoL. Besides, given that nCRT has only limited
benefit on overall survival, but a detrimental effect on func-
tion, we agree with the suggestion that the selection of pa-
tients for neoadjuvant therapy should be more conservative
[38].
Hence our findings emphasize the implementation of
pre-treatment counseling to inform patients of the risk of
bowel dysfunction, routine postoperative screening for
bowel dysfunction along with a need for more individually
targeted follow-up and support in rectal cancer patients
and increased awareness about not only oncological but
also long-term functional outcome among surgeons
[6, 38, 47].
Certain limitations to this study should be considered.
First, due to single center design of the present study, estab-
lishing the temporality between cause and effect as well as
generalizing our findings to overall rectal cancer population
seems difficult. Second, relatively low sample size might
prevent us to achieve the statistical significance concerning
the change in study parameters with respect to tumor loca-
tion. Third, while functional assessments were performed
after the first postoperative year in almost 80 % of our
patients, due to retrospective design of the study, lack post-
operative duration prior to functional assessments was not
standard and varied between patients. This may affect the
results of functional assessments. Nevertheless, despite
these certain limitations, given the paucity of the solid
information available on this area, our findings represent a
valuable contribution to the literature.In conclusion, our
findings indicate significant late adverse effects of nCRT
and sphincter preserving surgery on bowel dysfunction and
QoL, particularly in the concomitant presence of urgency
symptom, in rectal cancer patients. Given the association of
manometrical findings on anorectal dysfunction with QoL,
our findings emphasize the importance of manometrical
evaluation in patients undergoing transient ileostomy fol-
lowing LAR operation prior to the stomal closure. Hence,
identifying the patients with a high risk of developing func-
tional anal impairment as well as the systematic registration
of not only oncological but also functional and QoL related
outcome seem important in all patients in the long-term
disease follow-up. Further investigation is necessary to de-
velop comprehensive assessment models for identification
and careful selection of patients who are good candidates
for restorative operations which would yield a baseline
reference for new treatment modalities in patients who are
at risk of experiencing late adverse effects of treatment.
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